APOE ε4's impact on response to amyloid therapies in early symptomatic Alzheimer's disease: Analyses from multiple clinical trials.
Saved in:
| Title: | APOE ε4's impact on response to amyloid therapies in early symptomatic Alzheimer's disease: Analyses from multiple clinical trials. |
|---|---|
| Authors: | Evans CD; Eli Lilly and Company, Indianapolis, Indiana, USA., Sparks J; Eli Lilly and Company, Indianapolis, Indiana, USA., Andersen SW; Eli Lilly and Company, Indianapolis, Indiana, USA., Brooks DA; Eli Lilly and Company, Indianapolis, Indiana, USA., Hauck PM; Eli Lilly and Company, Indianapolis, Indiana, USA., Mintun MA; Eli Lilly and Company, Indianapolis, Indiana, USA.; Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, Philadelphia, Pennsylvania, USA., Sims JR; Eli Lilly and Company, Indianapolis, Indiana, USA. |
| Source: | Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2023 Dec; Vol. 19 (12), pp. 5407-5417. Date of Electronic Publication: 2023 May 19. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: John Wiley & Sons, Ltd Country of Publication: United States NLM ID: 101231978 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-5279 (Electronic) Linking ISSN: 15525260 NLM ISO Abbreviation: Alzheimers Dement Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1552-5279 |
|---|---|
| DOI: | 10.1002/alz.13128 |
